The Effect of Melatonin on Gene Expression and Activity of the Sirt1 and Its Target Genes Catalase and MnSOD in Multiple Sclerosis Patients and Healthy Subjects

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02463318

Enrollment

Registered

2015-06-04

Start date

2012-09-30

Completion date

2015-09-30

Last updated

2017-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis, Oxidative Stress

Keywords

Multiple sclerosis, SIRT1, MnSOD, Catalase, Oxidative stress, Antioxidant enzyme

Brief summary

The purpose of this study is to investigate the gene expression and activity of SIRT1, and forkhead box O3 pathway by means of investigating target genes MnSOD and catalase in multiple sclerosis and healthy subjects. Also, we investigate the effect of melatonin on interaction between SIRT1 activity and target genes MnSOD and catalase in multiple sclerosis and healthy subject .Additionally, we evaluate effect the probable effect of melatonin treatment on gene expression and activity of above-mentioned genes in peripheral blood mononuclear cells of healthy subjects-treated with H2O2.

Interventions

DRUGMelatonin

Melatonin is used for healthy subjects and multiple sclerosis patients

OTHERHydrogen peroxide

Hydrogen peroxide is only used for healthy subjects

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

patients with relapsing-remitting multiple sclerosis. The diagnosis of MS was based on the McDonald criteria . All patients were newly diagnosed cases with an Expanded Disability Status Scale (EDSS) score ≤ 6 and had never received immunomodulatory and immunosuppressive drugs. \-

Exclusion criteria

* The

Design outcomes

Primary

Measure	Time frame
Relative gene expression by real-time PCR (polymerase chain reaction)	Change from baseline after 12-hour treatment with melatonin and 2 -hours treatment with H2O2

Secondary

Measure	Time frame
MnSOD enzyme activity assay	Change from baseline after 12-hour treatment with melatonin and 2 -hours treatment with H2O2
Catalse enzyme activity assay	Change from baseline after 12-hour treatment with melatonin and 2 -hours treatment with H2O2
SIRT1 enzyme activity assay	Change from baseline after 12-hour treatment with melatonin and 2 -hours treatment with H2O2

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026